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ABSTRACT
DEVELOPMENT OF METHODS TO EVALUATE THE USE OF
ME-DI-551 TO TARGET CD19 TRANSMEMBRANE PROTEINS
ON B-CELLS TO IMPROVE SYSTEMIC SCLEROSIS
Natalia Dohman
Director: Dr. Victor Huber, Ph.D.

Systemic sclerosis, a subcategory of scleroderma, is a rare autoimmune
disease that affects the skin and, in some cases, the internal organs of those
diagnosed with the disease. There is currently no cure for this disease, only
treatments to slow its progression. It is important to note that each individual
diagnosed with scleroderma experience differences in severity and symptoms of
the disease and are treated based on their symptoms, not as a whole. Many factors
of this disease still remain unknown, such as what causes the disease or stimulates
the onset of it. Recent studies have helped determine different treatment options
for those diagnosed with the disease. For example, studies have been conducted
using MEDI-551 , a monoclonal antibody that targets CD19 transmembrane
proteins, as form of treatment that could further improve systemic sclerosis. Here
we present an initial evaluation of antibody therapies on whole cells as a way to
start testing a therapeutic like MEDI-551 for its efficacy in kilting B cells through
either direct or indirect interactions with the immune system. Our findings
discussed in the context of the disease state and the future of treatment using
monoclonal antibody therapies.
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CHAPTER ONE
Introduction
Systemic sclerosis is an autoimmune disease that affects the skin and, in
some cases, internal organs of those diagnosed with the disease. There is currently
no cure for this disease, only treatments to slow its progression. Recent studies
have been conducted using MEDI-551 , a monoclonal antibody that targets CD19
transmembrane proteins, as form of treatment that could further improve diffuse
systemic sclerosis from the treatments currently in use. The main objective of this
thesis is to provide knowledge on systemic sclerosis and to elaborate on a new
treatment for the disease. In order to better understand how the new treatment
works effectively, it is important to understand systemic sclerosis, its symptoms,
and former treatments.
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Figure 1. This figure shows the Serial Dilution Scheme used for the preparation
of the primary antibody, cetuximab. These dilutions were then pipetted into
the wells according to Table 1.
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